Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-α by Hung, W-C & Chuang, L-Y
Interferons (IFNs) are cytokines that are involved in the regulation
of diverse cellular functions, including modulation of immune
responses, inhibition of proliferation, and induction of resistance
to viral and bacterial infection (Gutterman, 1994). IFNs employ a
unique signalling pathway for rapid induction of gene expression
by utilizing two groups of critical elements to transduce the signals
from cell surface receptor to nuclear events. The first is the janus
family kinases (JAKs), a group of tyrosine kinases containing
JAK1, JAK2, JAK3 and TYK2, and the second is STAT (signal
transducers and activators of transcription) proteins, a group of
latent cytoplasmic transcription factors which are activated by
phosphorylation (Darnell, 1997; Pellegrini and Dusanter-Fourt,
1997). Upon IFN stimulation, receptor-associated JAKs are phos-
phorylated and activated and these kinases, in turn, phosphorylate
and activate STAT proteins which then translocate from cytoplasm
to nucleus and direct transcriptional activation of various effector
genes. The essential role of JAKs and STATs in IFN signalling
pathway has been demonstrated by the IFN-resistant phenotypes
of cells lacking the JAK or STAT gene products (Muller et al,
1993; Xu et al, 1994).
Recent studies have shown that IFNs are the most promising
anti-viral agents for the treatment of patients with chronic hepatitis
B. These cytokines have been reported to suppress hepatitis B
virus (HBV) enhancer activity, reduce virus replication and
activate hepatocellular gene expression in cultured liver cells
(Tur-Kaspa et al, 1990; Zhang and McLachlan, 1994).
Additionally, results from clinical trials also demonstrated that
IFNs caused inhibition of HBV replication and reduction of
hepatitis B surface antigen (HBsAg) expression (Alexander et al,
1987; Korenman et al, 1991). These studies suggest that IFNs are
useful anti-viral drugs for the treatment of patients with viral
hepatitis. However, the use of IFNs in the therapy of liver cancer
seems discouraging. Although several studies have shown that
IFNs exerted growth-inhibitory effects on human hepatoma cells
(Lai et al, 1989; Boue et al, 1990), other works showed that
patients with advanced hepatocellular carcinoma were resistant to
IFNs (Nair et al, 1985; Sachs et al, 1985). However, the molecular
basis of this resistance is not clear.
Recent studies have indicated that the responses of cells to
IFNs could be modulated by regulating the expression or the
activity of JAKs and STATs. It has been found that elevated
activity of JAKs enhanced the anti-tumour effects of IFNs to
lymphoblastoid cells (Lee et al, 1997). Similarly, induction of
STATs gene expression by retinoic acids in IFN-unresponsive
breast cancer cells and myeloid leukaemia cells permitted growth
inhibition by IFNs (Kolla et al, 1996; Weihua et al, 1997). These
data suggest that the resistance of cancer cells to IFNs may be
due to a relative deficiency of IFN signalling molecules and argue
that overexpression of these signalling molecules may restore
the responsiveness of cancer cells to IFNs. Among the drugs
Sodium butyrate enhances STAT 1 expression in
PLC/PRF/5 hepatoma cells and augments their
responsiveness to interferon-a
W-C Hung1 and L-Y Chuang2
1School of Technology for Medical Sciences and 2Department of Biochemistry, Kaohsiung Medical College, No. 100, Shih-Chuan 1st Road, Kaohsiung 807,
Taiwan, Republic of China
Summary Although interferon-a (IFN-a) has shown great promise in the treatment of chronic viral hepatitis, the anti-tumour effect of this
agent in the therapy of liver cancer is unclear. Recent studies have demonstrated that differentiation-inducing agents could modulate the
responsiveness of cancer cells to IFN-a by regulating the expression of signal transducers and activators of transcription (STAT) proteins, a
group of transcription factors which play important roles in the IFN signalling pathway. We have reported that sodium butyrate is a potent
differentiation inducer for human hepatoma cells. In this study, we investigated whether this drug could regulate the expression of STAT
proteins and enhance the anti-tumour effect of IFN-a in hepatoma cells. We found that sodium butyrate specifically activated STAT1 gene
expression and enhanced IFN-a-induced phosphorylation and activation of STAT1 proteins. Co-treatment with these two drugs led to G1
growth arrest, accompanied by down-regulation of cyclin D1 and up-regulation of p21WAF-1, and accumulation of hypophosphorylated
retinoblastoma protein in hepatoma cells. Additionally, internucleosomal DNA fragmentation, a biological hallmark of apoptosis, was detected
in hepatoma cells after continuous incubation with a combination of these two drugs for 72 h. Our results show that sodium butyrate potently
enhances the anti-tumour effect of IFN-a in vitro and suggest that a rational combination of these two drugs may be useful for the treatment
of liver cancer.
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effective both in enhancing STATs expression and in promoting
IFN-a-induced cell growth arrest in different tumour types (Goto
et al, 1996; Pelicano et al, 1997). We have previously demon-
strated that sodium butyrate, a natural fermentation product of
colonic bacterial flora, induced differentiation in PLC/PRF/5
hepatoma cells (Hung et al, 1995). In this study, we investigated
whether sodium butyrate modulated the expression of STATs in
PLC/PRF/5 cells and altered the sensitivity of these cells to IFN-a.
MATERIALS AND METHODS
Reagents
Human recombinant IFN-a was kindly provided by Hoffmann-La
Roche Inc. Antibodies against the members of the STAT gene
family (STAT1–6) were obtained from Transduction Laboratories
(Lexington, KY, USA) and monoclonal antibodies against human
cyclin D1 and p21WAF-1 were purchased from Calbiochem
(San Diego, CA, USA). Anti-human retinoblastoma protein (pRB)
antibody was obtained from Pharmingen (San Diego, CA, USA)
and sodium butyrate and other chemicals were purchased from
Sigma (St Louis, MO, USA).
Cell culture and treatment
PLC/PRF/5 cells were cultured in Dulbecco’s modified Eagle
medium: nutrient mixture F12 (DMEM/F12) supplemented with
10% heat-inactivated fetal calf serum (FCS) in a 5% carbon
dioxide incubator at 378C. Cells were grown in 10% FCS medium
to subconfluence and then incubated in medium containing
sodium butyrate (1 mM) or IFN-a (200–2000 IU ml21) alone,
or a combination of these two drugs for different time intervals,
and were harvested for analysis.
Analysis of cell cycle phase by flow cytometry
The drug-treated cells were trypsinized, washed with phosphate-
buffered saline (PBS) and fixed in 95% ethanol at 2 208C for 1 h.
Following collection, cells were resuspended in 400 ml of PBS
containing 1 mg ml21 RNAase and 0.5% Triton X-100, incubated
at room temperature for 1 h and stained with 50 mg ml21 of
propidium iodide for another 30 min. Fluorescence emitted from
the propidium iodide–DNA complex was analysed by FACScan
flow cytometry (Becton Dickinson) and cell cycle distribution was
calculated with the CellFit software.
Immunoprecipitation and immunoblotting
After treatment, cells were washed with ice-cold PBS and
harvested in a lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM,
sodium chloride, 5 mM EDTA, 1% Triton X-100, 50 mM sodium
fluoride (NaF), 1 mM sodium orthovanadate, 1 mM phenylmethyl-
sulphonyl fluoride, 2 mg ml21 pepstatin A, 2 mg ml21 leupeptin and
1 mg ml21 aprotinin) for 20 min on ice and centrifuged at 12 000 g
for 20 min. Protein concentration of lysates was determined by
using a Bio-Rad protein assay kit. For immunoprecipitation,
normalized volumes of extracts containing 500 mg protein were
incubated for 4 h at 48C with specific antibodies. Immuno-
complexes were collected following incubation with protein G-
agarose beads at 48C for another 1 h. The beads were washed three
times with lysis buffer and the immunocomplexes were eluted by
boiling in the Laemmli sample buffer. Equal volumes of eluted
immunocomplexes were then subjected to immunoblotting
analysis. For immunoblotting, eluted immunocomplexes or cell
lysates (50 mg protein per sample) were subjected to sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were transferred to nitrocellulose filters and the
blots were blocked overnight at 48C in 5% non-fat milk in TBST
(20 mM Tris–HCl, pH 7.4, 137 mM sodium chloride and 0.05%
Tween-20). The blots were washed in TBST and incubated with
various antibodies for 2 h at room temperature. After extensively
washing in TBST buffer, peroxidase-conjugated secondary anti-
body was added in blocking buffer for another 1 h and the blots
were developed by using the ECL chemiluminescence system
(Amersham). The signal intensities of immunoblots were quanti-
fied by densitometric scanning.
Electrophoretic mobility shift assay
Nuclear extract preparation and electrophoretic mobility shift
assay EMSA analysis was performed as previously described
(Decker et al, 1991). In brief, a double-stranded oligonucleotide
corresponding to the GAS element found within the promoter of
the guanylate-binding protein (GBP) gene was synthesized and
end-labelled using polynucleotide kinase and [g-32P]-adenosine
5¢-triphosphate (ATP) and incubated with nuclear extracts for
20 min at room temperature. The oligonucleotide–protein
complexes were fractionated on a 6% non-denatured polyacry-
lamide gel and detected by autoradiography. For competition, a
20-fold excess of unlabelled oligonucleotides or 1 mg anti-STAT 1
or anti-c-Jun antibodies were added to reaction mixture.
Morphological analysis of apoptotic cells
Cells were cultured in 6-well plates in complete medium
containing different combinations of drugs for 72 h. After incuba-
tion, detached cells were pelleted by centrifugation and attached
cells were harvested by trypsinization. Cells were pooled and
collected at 3000 g for 10 min and washed twice with PBS. Cells
were fixed with 3% paraformaldehyde in PBS for 15 min
at room temperature and stained with Hoechst 33258 dye for
another 15 min at room temperature. Stained cells were placed
on glass slides and observed under a fluorescence microscope. For
each sample, 500 cells were counted and apoptotic cells with
condensed chromatin fragments were scored and expressed as a
percentage of total cell number measured.
DNA extraction and agarose gel electrophoresis
After drug incubation, cells were harvested and genomic DNA
was extracted and analysis of DNA fragmentation on agarose gel
was performed as described previously (Hung and Chuang, 1996).
RESULTS
Specific induction of STAT1 expression by sodium
butyrate in PLC/PRF/5 cells
Our previous results have indicated that sodium butyrate is a
potent differentiation-inducing agent to PLC/PRF/5 hepatoma
cells. This agent effectively inhibited a-fetoprotein secretion,
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acquire in vitro properties which were more consistent with well-
differentiated cells in a dose-dependent manner (Hung et al, 1995).
Since sodium butyrate at 1 mM induced phenotypic changes in
PLC/PRF/5 cells as described above and did not show any cyto-
toxicity in these cells after a 3-day treatment, we therefore
routinely used 1 mM sodium butyrate to treat cells in this work.
Similar results were observed when higher concentrations of
sodium butyrate were added (data not shown). We first asked
whether sodium butyrate modulated the expression of STATs in
this cell line. As shown in Figure 1, PLC/PRF/5 cells cultured in
10% FCS medium constantly expressed all STATs, except STAT4,
proteins. However, significant differences between the expression
levels of STATs in this cell line were found. PLC/PRF/5 cells
expressed a large amount of STAT6 and a relatively smaller
amount of STAT1, STAT3 and STAT5, while very little amount of
STAT2 was detected. Lack of STAT4 in PLC/PRF/5 cells is not
surprising because the expression of STAT4 has been reported to
be limited to thymus, spleen and testis (Yamamoto et al, 1994).
The difference between the expression of STATs was further
confirmed by probing the membrane with anti-b-actin antibody to
verify equal loading of proteins in each lane. Figure 1 also shows
that sodium butyrate did not regulate the expression of STAT 3, 5,
6 in PLC/PRF/5 cells after a 48-h incubation and this agent slightly
decreased the protein level of STAT2 under the same experimental
conditions. Conversely, the expression of STAT1 was significantly
(a 2.25-fold increase) enhanced after treatment with sodium
butyrate for 2 days. Also, the difference in protein levels of STATs
detected by immunoblotting is not due to the difference of quality
of the used antibodies, because positive controls (lystates of Jurkat
human leukaemia cells or rat testis provided by the manufacturer
of antibodies) were included in our immunoblotting assays to
confirm the results. Furthermore, the relative signal intensities of
STATs (normalized with the signal intensities of b-actin) after
sodium butyrate treatment are shown in Table 1.
Sodium butyrate enhances the activation of STAT1 by
IFN-a
Since sodium butyrate significantly up-regulates the expression of
STAT1, we investigated whether IFN-a-induced phosphorylation
and activation of STAT1 was enhanced in sodium butyrate-
pretreated PLC/PRF/5 cells. The phosphorylation status of STAT1
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Figure 1 Regulation of STATs expression by sodium butyrate in PLC/PRF/5
cells. Cells were treated with 1 mM sodium butyrate for different time intervals
and harvested in a lysis buffer. In each lane, 50 mg protein of each
preparation were separated by SDS-PAGE, transferred to nitrocellulose
membrane and subjected to immunoblotting analysis. The blots were probed
with specific anti-STAT antibodies and developed by using a
chemiluminescence substrate kit
Table 1 Alteration of protein levels of STATs in PLC/PRF/5 cells after
sodium butyrate treatment
Ratio (STAT intensity/b-actin intensity)
STATs 2 sodium butyrate 1 sodium butyrate Fold increase
STAT1 0.20 6 0.05 0.45 6 0.05a 2.25
STAT2 0.13 6 0.04 0.11 6 0.03 0.85
STAT3 0.45 6 0.09 0.50 6 0.17 1.11
STAT5 0.29 6 0.08 0.33 6 0.14 1.13
STAT6 0.84 6 0.15 0.90 6 0.12 1.07
Cells were cultured in the absence or presence of 1 mM sodium butyrate for
48 h and immunoblotting analysis was performed as described in Figure 1.
Signal intensities of STATs were quantified by densitometric scanning and
then normalized with signal intensities of b-actin. The values represent mean
6 s.d. of three different experiments. Significance of differences between
cells treated without or with 1 mM sodium butyrate was calculated by using
Student’s t-test, aP , 0.01.
IB: anti-STAT1
0 0.2 2 0 0.2 2
Sodium butyrate
Interferon-a (x 10
3 IU ml–1)
STAT1
IP: anti-STAT1
STAT1
IP: anti-STAT1
–––+++
IB: anti-phosphotyrosine
Figure 2 IFN-a-induced phosphorylation of STAT1 was enhanced by
sodium butyrate. Cells were cultured in the absence or presence of 1 mM
sodium butyrate for 2 days and then stimulated with different concentrations
of IFN-a for 30 min. Whole cell lysates were isolated and protein
concentrations were determined. For each sample, 300 ml of whole cell
lysates containing 500 mg of cellular proteins was immunoprecipitated with
1 mg anti-STAT1 monoclonal antibody at 48C for 4 h. Immunocomplexes were
collected by adding the protein G-agarose beads and eluted by boiling in the
Laemmli sample buffer. Immunoprecipitates were separated by SDS-PAGE,
transferred to nitrocellulose membranes and probed with anti-STAT1 or
antiphosphotyrosine antibodies. IP: immunoprecipitation. IB: immunoblotting
Table 2 Effect of sodium butyrate and IFN-a on cell cycle progression in
PLC/PRF/5 cells analysed by flow cytometric analysis
Cell cycle distribution (%)
Treatment G1 S G2/M
Control (no addition) 43.2 41.7 15.1
Sodium butyrate (1 mM) 53.9 31.6 14.5
IFN-a (2000 IU ml21) 61.3 25.7 13.0
Sodium butyrate + IFN-a 83.8 7.1 9.1was studied by immunoprecipitation and immunoblotting tech-
nique. Cells were preincubated with sodium butyrate for 2 days
and then stimulated with different concentrations of IFN-a for
30 min. STAT1 protein was immunoprecipitated by a specific
monoclonal antibody, resolved by SDS-PAGE and transferred to
nitrocellulose membranes. The blots were then probed with an
anti-phosphotyrosine antibody to investigate the phosphorylation
status of STAT1. As demonstrated in Figure 2, phosphorylation of
STAT1 was slightly induced by IFN-a in PLC/PRF/5 cells. After
sodium butyrate pretreatment, IFN-a-induced phosphorylation of
STAT1 was significantly enhanced, but sodium butyrate alone did
not affect the phosphorylation status of STAT1. Because STAT1 is
activated by phosphorylation, we next examined whether the DNA
binding activity of STAT1 was also augmented by sodium butyrate
in PLC/PRF/5 cells. It is well-known that IFN-a can regulate
various gene expressions via two promoter motifs called the
IFN-stimulated response element (ISRE) and the IFN-g activation
site (GAS), which bind the primary factor IFN-stimulated gene
factor-3 (ISGF-3) and IFN-g activation factor (GAF) respectively.
The ISGF-3 complex contains phosphorylated STAT1, STAT2 and
a p48 protein, and the GAF complex mainly contains phosphoryl-
ated STAT1:STAT1 homodimer or STAT1:STAT3 heterodimer.
Because the foregoing experiments indicated that the expression
of STAT2 was very low in PLC/PRF/5 cells and the expression of
STAT1 was specifically activated by sodium butyrate, we there-
fore used a GAS oligonucleotide probe to evaluate the DNA
binding activity of STAT1. Figure 3 shows that IFN-a activated
GAF binding to GAS in PLC/PRF/5 cells in a dose-dependent
manner. Interestingly, two gel shift complexes (GAF-1 and
GAF-2) with similar characteristics were observed in our EMSA
autoradiographs. Similar results have also been reported in
HL60 and WISH cells after IFN-a stimulation, and these
complexes have been shown to be STAT1:STAT3 (GAF-1)
heterodimer and STAT1:STAT1 (GAF-2) homodimer respectively
(Pelicano et al, 1997). The identity of these gel shift complexes
as GAFs containing STAT1 was established by specific anti-
STAT1 antibodies that neutralized the formation of GAF
complexes but not by unrelated anti-c-Jun antibodies.
Furthermore, unlabelled GAS oligonucleotides competed
efficiently for GAF binding. Taken together, these data
indicate that IFN-a-induced phosphorylation and activation of
STAT1 is enhanced by sodium butyrate in PLC/PRF/5 cells.
Sodium butyrate and IFN-a synergistically induce G1
growth arrest and apoptosis in PLC/PRF/5 cells
Because sodium butyrate-preincubated PLC/PRF/5 cells showed
an increase in phosphorylation and activation of STAT1 after a
short-term stimulation of IFN-a, it is of interest to determine if
sodium butyrate can modulate the biological responses to IFN-a in
these cells after a long-term culture. Thus, cells were treated with
different combinations of drugs and cell cycle distribution was
examined by flow cytometry. As shown in Table 2, the percentage
of cells accumulated in G1 phase after treatment with 1 mM
sodium butyrate or 2000 IU ml21 IFN-a for 48 h was 54% and
61%, respectively, while the percentage of G1 cells was 43% in
untreated cells. However, 84% of cells were in G1 phase after
incubation of PLC/PRF/5 cells with 2000 IU ml21 IFN-a and
sodium butyrate simultaneously for 48 h. These results indicate
that cell cycle progression was arrested in G1 phase. We further
investigated the effect of these two drugs on the expression of cell
cycle regulatory proteins in PLC/PRF/5 cells. As demonstrated in
Figure 4, sodium butyrate (1 mM) or IFN-a (2000 IU ml21) alone
slightly decrease the expression of cyclin D1, but simultaneous
incubation of these two drugs completely inhibits the expression
of cyclin D1. Furthermore, these two drugs synergistically
activated the expression of p21WAF-1, a specific cyclin-dependent
kinase (CDK) inhibitor. Up-regulation of p21WAF-1 and down-
regulation of cyclin D1 leads to accumulation of hypophos-
phorylated form of retinoblastoma (Rb) proteins in these cells
(Figure 4). Additionally, we found that cell viability was
dramatically decreased after co-treatment of these two drugs for
3 days. After drug treatment for 48 or 72 h, cells were fixed and
stained with the fluorochrome Hoechst 33258, and apoptotic cells
with condensed chromatin fragments were observed under a
fluorescence microscope and scored. The percentage of apoptoic
nuclei in cells co-treated with sodium butyrate and IFN-a for
72 h is about 50%, but incubation with either drug alone did not
significantly affect cell viability under the same experimental
conditions (Table 3). Additionally, a characteristic DNA ladder
pattern of DNA fragmentation was induced by co-treatment of
these two drugs in PLC/PRF/5 cells (Figure 5). Conversely,
incubation of sodium butyrate or IFN-a alone for 3 days did not
induce DNA fragmentation in these cells. Thus, it is suggested that
long-term treatment of sodium butyrate in combination with
IFN-a may trigger apoptosis in PLC/PRF/5 hepatoma cells.
DISCUSSION
The molecular mechanism for the deficiency of effects of IFNs in
the inhibition of proliferation in hepatoma cells is not well defined,
it is suggested that the insufficiency of expressions of important
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Figure 3 Sodium butyrate enhancement of STAT1 activation by IFN-a in
PLC/PRF/5 cells. Cells were first cultured in the absence or presence of 1 mM
sodium butyrate for 2 days and stimulated with different concentrations of
IFN-a for 30 min. Nuclear extracts were prepared and electrophoretic mobility
shift assays were performed as described in Materials and Methods. For
competition experiments, specific unlabelled probes (20 X), anti-STAT1 or
anti-c-Jun antibodies (1 mg) were added into the reaction mixturesignal transducers in the IFN-mediated pathway in human
hepatoma cells may be responsive partially for this deficiency.
Therefore, we tested whether enhancement of the expressions of
these signal transduction molecules in human hepatoma cells may
restore the response of these cells to IFNs. We found that the
expression of STAT1, a transcription factor involved in the
IFN-mediated signalling system, is specifically activated by
sodium butyrate, and phosphorylation and activation of STAT1
induced by IFN-a is also significally enhanced by this drug. In
agreement with our expectation, sodium butyrate augments the
anti-proliferative effect of IFN-a. Pretreatment of IFN-unrespon-
sive tumour cell lines with retinoic acid, another potent differenti-
ation-inducing agent, also permitted growth inhibition by IFNs
(Pelicano et al, 1997; Weihua et al, 1997). These studies indicated
that augmentation of the expression of STAT1 by retinoic acid is
an early step in the cooperative anti-tumour effects of retinoic acid
and IFNs. In addition to in vitro study, clinical studies also demon-
strated that IFN-a and 13-cis-retinoic acid produced substantial
therapeutic benefits in patients with advanced squamous cell
carcinomas of the skin and cervix (Lippman et al, 1992a, 1992b).
Therefore, it is suggested that a rational combination of IFNs and
differentiation-inducing agents may help to develop a new strategy
for the treatment of human cancer. Our results support this idea
and define a molecular basis for the synergy between IFNs and
sodium butyrate in hepatoma growth inhibition. Furthermore, a
recent study has reported that hepatitis B viral terminal protein
shuts off IFN-induced gene expression by interfering with the
formation of ISGF-3 and inhibited cellular responses to IFN-a and
IFN-g (Foster et al, 1991). The authors suggested that, in patients
with chronic hepatitis B virus infection, an imbalance in HBV
RNA and polymerase production may generate sufficient free
polymerases or terminal proteins to give rise to IFN-resistant cells.
Clinically, this may be one of the mechanisms by which patients
develop resistance to IFN therapy during chronic viral infection.
Considered together, our results are of clinical importance in the
treatment of viral hepatitis and liver cancer.
Another important observation in our study is the synergy
between IFN-a and sodium butyrate in the induction of p21WAF-1
expression. This protein was originally identified as a CDK2-
interactive protein by using the yeast two-hybrid technique
and was found to be a CDK inhibitor (Harper et al, 1993).
Subsequently, accumulating data suggested that p21WAF-1 is a
critical mediator of p53-mediated G1 phase arrest (El-Deiry et al,
1993, 1994). Many human cancer cells (including hepatoma cells)
harbour mutant p53 proteins, these cells do not arrest in the G1
phase and do not accumulate p21WAF-1 after DNA-damaging agent
treatment, thus resulting in de-regulated cell growth control. It has
been demonstrated that p21WAF-1 expression can be induced via
p53-independent pathways and enforced expression of this protein
in cancer cells harbouring mutant p53 proteins may induce G1
phase arrest and inhibit tumour growth (Xiong et al, 1993; Harper
et al, 1995). Recent study showed that IFNs might trigger expres-
sion of p21WAF-1 via STAT1 sites (Chin et al, 1996). Thus, sodium
butyrate may act via up-regulation of STAT1 expression to
enhance IFN-a-induced p21WAF-1 expression in PLC/PRF/5 cells.
However, it is also possible that sodium butyrate may act via Sp1
sites independently to activate p21WAF-1 expression as reported
recently (Nakano et al, 1997). Study of the collaboration between
different consensus sites in p21WAF-1 promoter will be helpful for
the understanding of regulation of p21WAF-1 expression in cells
receiving different stimuli or insults.
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Figure 4 Growth inhibition of PLC/PRF/5 hepatoma cells by sodium
butyrate and IFN-a is associated with modulation of cyclin D1 and p21WAF-1
expression and RB phosphorylation. Cells were treated with sodium butyrate
(1 mM) or IFN-a (2000 IU ml21) or a combination of these two drugs for 2
days. Cells were harvested in a lysis buffer and analysis of expression of cell
cycle regulatory proteins was performed by immunoblotting as described in
Figure 1
––++
–+ – +
M IFN-a
Sodium butyrate
Figure 5 Induction of a DNA ladder pattern of DNA fragmentation by
sodium butyrate/IFN-a combination in PLC/PRF/5 cells. Cells were cultured
in sodium butyrate (1 mM) or IFN-a or a combination of these two drugs for 3
days. Cells were collected in a lysis buffer and genomic DNA was extracted.
DNA samples were subjected to agarose gel electrophoresis, stained with
ethidium bromide and visualized under UV light
Table 3 Cotreatment of sodium butyrate and IFN-a induces apoptosis in
PLC/PRF/5 cells
Apoptotic cells (% of total cell number)
Treatment 48 h 72 h
Control (no addition) 3 6 28   6 2
Sodium butyrate (1 mM)4   6 1 10 6 3
IFN-a (2000 IU ml21)8   6 3 14 6 2
Sodium butyrate 1 IFN-a 11 6 5 48 6 8
Cells were cultured in different combinations of drugs for 3 days. After that,
cells were harvested, stained with Hoechst 33258 dye and counted under a
fluorescence microscope. The values represent mean 6 s.e.m. of three
independent experiments.We also found that apoptosis of PLC/PRF/5 cells could be
induced by a combination of sodium butyrate and IFNs. Although
the mechanism by which these two drugs trigger apoptotic cell
death is unclear, recent works demonstrated that activation of the
STAT signalling pathway may cause expression of caspase-1 and
induction of apoptosis (Chin et al, 1997). Caspase-1, originally
known as interleukin-1b-converting enzyme (ICE), is a member
of the mammalian ICE protease family which plays an important
role in the executing phase of apoptosis and is homologous to the
C. elegans protein ced-3 (Kumar, 1995). These proteases are
thought to induce cell death by cleaving vital cellular proteins
(such as nuclear lamins, poly(ADP)-ribose polymerase, U1-asso-
ciated 70 kDa protein etc.). It has also been identified that several
caspases may be activated simultaneously or sequentially by
different apoptotic signals. Whether ICE/ICE-like proteases are
involved in the apoptotic signalling pathway induced by sodium
butyrate and IFN-a needs further investigation. In summary, our
results demonstrate that the combination of sodium butyrate and
IFN-a is highly effective in the inhibition of hepatoma cell pro-
liferation in vitro and may lead to additional therapeutical
approaches against both liver cancer and viral infectious diseases.
Furthermore, due to its low cytotoxicity, sodium butyrate is
considered to be a better therapeutical adjuvant than other differ-
entiation-inducing agents (such as retinoic acid or dimethyl
sulphoxide).
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